Ambulatory Blood Pressure Reduction After Rosiglitazone Treatment In Normotensive Type 2 Diabetic Patients

Baskent University25 enrolled

Overview

The purpose of this study was to determine the effects of rosiglitazone in normotensive type 2 diabetic patients with regard to its blood-pressure-reducing effects.

The first study to evaluate the effects of troglitazone on blood pressure in humans was published recently, which demonstrated a 5/4 mm Hg reduction in ambulatory blood pressure in 18 nondiabetic obese subjects after 12 weeks' treatment. Another study in 18 hypertensive subjects with diabetes mellitus showed an 18/12 mm Hg decline in office blood pressure after 8 weeks of treatment.

Study Type

INTERVENTIONAL

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Diabetes Mellitus, Type 2

Interventions

rosiglitazone(drug), blood pressure lowering effectDRUG

Eligibility

Sex: ALLMin age: 49 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Blood pressure of patients were in normotensive limits according to the JNC VII * Diabetes mellitus treated with oral antidiabetics or diet Exclusion Criteria: * Any known hypertension, coronary artery disease, congestive hearth failure, renal disease or liver disease * Anti-hypertensive treatment

Locations (1)

Baskent University Ankara Hospital

Ankara, Turkey (Türkiye)

Outcomes

Primary Outcomes

Ambulatory blood pressure monitors used to determine the subjects blood pressure before and after the treatment. At the end of three months period wit rosiglitazone treatment diastolic blood pressure decreased.

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.